Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 17/20 | 0.49 |
| ▸ | HCK | P08631 | 15/20 | 0.49 |
| ▸ | MAPK12 | P53778 | 14/20 | 0.49 |
| ▸ | SRC | P12931 | 2/20 | 0.49 |
| ▸ | RIOK2 | Q9BVS4 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17017694 | 0.90 | MAPK14 (0.48) | MAPK14HCKMAPK12SRC | |
| SCHEMBL31086831 | 0.87 | MAPK14 (0.46) | MAPK14HCKMAPK12SRCRIOK2 | |
| SCHEMBL17004776 | 0.87 | MAPK14 (0.48) | MAPK14HCKMAPK12SRCRIOK2 | |
| SCHEMBL31086573 | 0.87 | MAPK14 (0.46) | MAPK14HCKMAPK12SRCRIOK2 | |
| SCHEMBL28578481 | 0.86 | HCK (0.39) | MAPK14HCKMAPK12SRCMRGPRX4 | |
| SCHEMBL18567055 | 0.85 | HCK (0.37) | MAPK14HCKMAPK12SRCMEN1 | |
| SCHEMBL31086877 | 0.84 | MAPK14 (0.44) | MAPK14HCKMAPK12SRC | |
| SCHEMBL17008524 | 0.83 | HCK (0.36) | MAPK14HCKMAPK12SRCMEN1 | |
| SCHEMBL17017125 | 0.83 | PIK3C3 (0.37) | MAPK14HCKMAPK12SRCMEN1 | |
| SCHEMBL18546368 | 0.82 | MAPK14 (0.39) | MAPK14HCKMAPK12SRCMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11142515-B2 | Pyrazolyl-ureas as kinase inhibitors | RESPIVERT LIMITED (GB) | 2021-10-12 | — | — | US | disclosed |
| EP-3418279-B1 | DRY POWDER PHARMACEUTICAL FORMULATION | RESPIVERT LTD (GB) | 2021-01-20 | — | — | EP | disclosed |
| US-10294216-B2 | Pyrazolyl ureas as kinase inhibitors | RESPIVERT LIMITED (GB) | 2019-05-21 | — | — | US | disclosed |
| EP-3418279-A1 | AROMATIC HETEROCYCLIC COMPOUNDS AS ANTIINFLAMMATORY COMPOUNDS | Respivert Limited (GB) | 2018-12-26 | — | — | EP | disclosed |
| EP-3105223-B1 | PYRAZOLYL-UREAS AS KINASE INHIBITORS | RESPIVERT LTD (GB) | 2018-09-12 | — | — | EP | disclosed |
| US-20180118719-A1 | PYRAZOLYL UREAS AS KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2018-05-03 | — | — | US | disclosed |
| EP-3105223-A1 | PYRAZOLYL-UREAS AS KINASE INHIBITORS | Respivert Limited (GB) | 2016-12-21 | — | — | EP | disclosed |
| WO-2015121660-A1 | PYRAZOLYL-UREAS AS KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2015-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10294216-B2 | Pyrazolyl ureas as kinase inhibitors | MAP3K1, MAP3K2, MAP3K8 | MAPK14 18/4885HCK 773/4885MAPK12 43/4885 |
| US-20180118719-A1 | PYRAZOLYL UREAS AS KINASE INHIBITORS | MAP3K1, MAPK1, MAP3K7 | MAPK14 16/4885HCK 553/4885MAPK12 37/4885 |
| US-11142515-B2 | Pyrazolyl-ureas as kinase inhibitors | MAPK1, MAP3K1, MAP3K8 | MAPK14 12/4885HCK 730/4885MAPK12 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.